In:
Hepatology Communications, Ovid Technologies (Wolters Kluwer Health), Vol. 5, No. 9 ( 2021-09), p. 1490-1506
Abstract:
CTNNB1 (catenin beta 1)–mutated hepatocellular carcinomas (HCCs) account for a large proportion of human HCCs. They display high levels of respiratory chain activity. As metabolism and redox balance are closely linked, tumor cells must maintain their redox status during these metabolic alterations. We investigated the redox balance of these HCCs and the feasibility of targeting this balance as an avenue for targeted therapy. We assessed the expression of the nuclear erythroid 2 p45‐related factor 2 (NRF2) detoxification pathway in an annotated human HCC data set and reported an enrichment of the NRF2 program in human HCCs with CTNNB1 mutations, largely independent of NFE2L2 (nuclear factor, erythroid 2 like 2) or KEAP1 (Kelch‐like ECH‐associated protein 1) mutations. We then used mice with hepatocyte‐specific oncogenic β‐catenin activation to evaluate the redox status associated with β‐catenin activation in preneoplastic livers and tumors. We challenged them with various oxidative stressors and observed that the β‐catenin pathway activation increased transcription of Nfe2l2 , which protects β‐catenin‐activated hepatocytes from oxidative damage and supports tumor development. Moreover, outside of its effects on reactive oxygen species scavenging, we found out that Nrf2 itself contributes to the metabolic activity of β‐catenin‐activated cells. We then challenged β‐catenin activated tumors pharmacologically to create a redox imbalance and found that pharmacological inactivation of Nrf2 was sufficient to considerably decrease the progression of β‐catenin‐dependent HCC development. Conclusion: These results demonstrate cooperation between oncogenic β‐catenin signaling and the NRF2 pathway in CTNNB1 ‐mediated HCC tumorigenesis, and we provide evidence for the relevance of redox balance targeting as a therapeutic strategy in CTNNB1 ‐mutated HCC.
Type of Medium:
Online Resource
ISSN:
2471-254X
,
2471-254X
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
2881134-3
Permalink
